Fischer Medical Ventures Share Price
Sector: Chemical Manufacturing
840.00 +2.00 (0.24%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
826
Today’s High
859.75
52 Week Low
513.10
52 Week High
919
Key Metrics
- Market Cap (In Cr) 5471.3
- Beta 0.79
- Div. Yield (%) 0
- P/B 55.27
- TTM P/E 1417.68
- Peg Ratio -40.82
- Sector P/E 0
- Open Price 826
- Prev Close 838
Fischer Medical Ventures Analysis
Price Analysis
-
1 Week0.58%
-
3 Months16.46%
-
6 Month36.67%
-
YTD19.03%
-
1 Year55.82%
Risk Meter
- 41% Low risk
- 41% Moderate risk
- 41% Balanced Risk
- 41% High risk
- 41% Extreme risk
Fischer Medical Ventures Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 20.98
- Selling/ General/ Admin Expenses Total
- 0.38
- Depreciation/ Amortization
- 0.18
- Other Operating Expenses Total
- 2.29
- Total Operating Expense
- 19.3
- Operating Income
- 1.68
- Net Income Before Taxes
- 2.11
- Net Income
- 1.84
- Diluted Normalized EPS
- 1.65
- Period
- 2024
- Total Assets
- 86.32
- Total Liabilities
- 5.21
- Total Equity
- 81.11
- Tangible Book Valueper Share Common Eq
- 14.75
- Period
- 2024
- Cashfrom Operating Activities
- -7.59
- Cashfrom Investing Activities
- -31.2
- Cashfrom Financing Activities
- 37.11
- Net Changein Cash
- -1.68
- Period
- 2023
- Total Revenue
- 0.18
- Selling/ General/ Admin Expenses Total
- 0.05
- Other Operating Expenses Total
- 0.12
- Total Operating Expense
- 0.16
- Operating Income
- 0.02
- Net Income Before Taxes
- 0
- Net Income
- -0.04
- Diluted Normalized EPS
- -2.12
- Period
- 2023
- Total Assets
- 0.35
- Total Liabilities
- 0.62
- Total Equity
- -0.27
- Tangible Book Valueper Share Common Eq
- -15.47
- Period
- 2023
- Cashfrom Operating Activities
- -0.15
- Cashfrom Financing Activities
- 0.17
- Net Changein Cash
- 0.02
- Period
- 2022
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0.08
- Other Operating Expenses Total
- 0.11
- Total Operating Expense
- 0.19
- Operating Income
- -0.19
- Net Income Before Taxes
- -0.2
- Net Income
- -0.23
- Diluted Normalized EPS
- -13.52
- Period
- 2022
- Total Assets
- 0.19
- Total Liabilities
- 0.42
- Total Equity
- -0.23
- Tangible Book Valueper Share Common Eq
- -13.34
- Period
- 2022
- Cashfrom Operating Activities
- -0.18
- Cashfrom Financing Activities
- 0.15
- Net Changein Cash
- -0.03
- Period
- 2021
- Total Revenue
- 0.16
- Selling/ General/ Admin Expenses Total
- 0.08
- Other Operating Expenses Total
- 0.1
- Total Operating Expense
- 0.18
- Operating Income
- -0.02
- Net Income Before Taxes
- -0.04
- Net Income
- 0.14
- Diluted Normalized EPS
- 8.18
- Period
- 2021
- Total Assets
- 0.25
- Total Liabilities
- 0.25
- Total Equity
- 0
- Tangible Book Valueper Share Common Eq
- 0.18
- Period
- 2021
- Cashfrom Operating Activities
- -0.06
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- -0.06
- Period
- 2020
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0.09
- Other Operating Expenses Total
- 0.12
- Total Operating Expense
- 0.21
- Operating Income
- -0.21
- Net Income Before Taxes
- -0.04
- Net Income
- -0.04
- Diluted Normalized EPS
- -2.39
- Period
- 2020
- Total Assets
- 0.14
- Total Liabilities
- 0.28
- Total Equity
- -0.14
- Tangible Book Valueper Share Common Eq
- -7.99
- Period
- 2020
- Cashfrom Operating Activities
- 0.01
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- 0.01
- Period
- 2019
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0.02
- Other Operating Expenses Total
- 0.17
- Total Operating Expense
- 0.19
- Operating Income
- -0.19
- Net Income Before Taxes
- 0.01
- Net Income
- 0
- Diluted Normalized EPS
- 0.26
- Period
- 2019
- Total Assets
- 0.11
- Total Liabilities
- 0.21
- Total Equity
- -0.1
- Tangible Book Valueper Share Common Eq
- -5.61
- Period
- 2019
- Cashfrom Operating Activities
- 0
- Cashfrom Financing Activities
- -0.03
- Net Changein Cash
- -0.03
- Period
- 2024-12-31
- Total Revenue
- 11.75
- Selling/ General/ Admin Expenses Total
- 0.75
- Depreciation/ Amortization
- 0.56
- Other Operating Expenses Total
- 2.97
- Total Operating Expense
- 11.81
- Operating Income
- -0.06
- Net Income Before Taxes
- 0.12
- Net Income
- -0.29
- Diluted Normalized EPS
- -0.05
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 39.66
- Selling/ General/ Admin Expenses Total
- 0.51
- Depreciation/ Amortization
- 0.29
- Other Operating Expenses Total
- 2.53
- Total Operating Expense
- 39.62
- Operating Income
- 0.04
- Net Income Before Taxes
- 0.21
- Net Income
- 0.29
- Diluted Normalized EPS
- 0.07
- Period
- 2024-09-30
- Total Assets
- 140.72
- Total Liabilities
- 59.27
- Total Equity
- 81.45
- Tangible Book Valueper Share Common Eq
- 14.52
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -19.75
- Cashfrom Investing Activities
- 20.83
- Cashfrom Financing Activities
- -0.13
- Net Changein Cash
- 0.95
- Period
- 2024-06-30
- Total Revenue
- 10.12
- Selling/ General/ Admin Expenses Total
- 0.39
- Depreciation/ Amortization
- 0.28
- Other Operating Expenses Total
- 1.38
- Total Operating Expense
- 10.66
- Operating Income
- -0.54
- Net Income Before Taxes
- 0.08
- Net Income
- -0.12
- Diluted Normalized EPS
- -0.02
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 20.79
- Selling/ General/ Admin Expenses Total
- 0.34
- Depreciation/ Amortization
- 0.18
- Other Operating Expenses Total
- 2.04
- Total Operating Expense
- 19.02
- Operating Income
- 1.78
- Net Income Before Taxes
- 2.2
- Net Income
- 2.03
- Diluted Normalized EPS
- 0.52
- Period
- 2024-03-31
- Total Assets
- 86.32
- Total Liabilities
- 5.21
- Total Equity
- 81.11
- Tangible Book Valueper Share Common Eq
- 14.75
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -7.59
- Cashfrom Investing Activities
- -31.2
- Cashfrom Financing Activities
- 37.11
- Net Changein Cash
- -1.68
- Period
- 2023-12-31
- Total Revenue
- 0
- Selling/ General/ Admin Expenses Total
- 0.03
- Depreciation/ Amortization
- 0
- Other Operating Expenses Total
- 0.12
- Total Operating Expense
- 0.15
- Operating Income
- -0.15
- Net Income Before Taxes
- -0.13
- Net Income
- -0.13
- Diluted Normalized EPS
- -0.76
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Fischer Medical Ventures Technical
Moving Average
SMA
- 5 Day851.99
- 10 Day810.36
- 20 Day808.23
- 50 Day815.01
- 100 Day766.73
- 300 Day703.66
Fischer Medical Ventures Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Rallis India
- 284.8
- -8.75
- -2.98
- 378.4
- 196
- 5538.47
- Sharda Cropchem
- 636.1
- 19.8
- 3.21
- 886.35
- 345
- 5710.82
- Fischer Medical Ventures
- 840
- 2
- 0.24
- 919
- 513.1
- 5471.3
- Laxmi Organic Industries
- 184.6
- -11.25
- -5.74
- 325.5
- 160.3
- 5127.42
- Refex Industries
- 408.9
- 4.4
- 1.09
- 600
- 124.55
- 5282.26
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Rallis India
- 46.7
- 3.05
- 8.91
- 5.69
- Sharda Cropchem
- 18.67
- 2.27
- 12.63
- 7.18
- Fischer Medical Ventures
- 519.73
- 56.56
- 4.18
- 7.82
- Laxmi Organic Industries
- 45.33
- 3.08
- 13.23
- 5.81
- Refex Industries
- 33.82
- 4.46
- 26.03
- 6.92
Fischer Medical Ventures Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 26-Mar-25
- Others
- 14-Feb-25
- Quarterly Results
- 03-Jan-25
- Others
- 13-Nov-24
- Quarterly Results
- 14-Aug-24
- Quarterly Results & Preferential issue
- 30-May-24
- Audited Results
- 04-May-24
- Others
- 12-Feb-24
- Quarterly Results
- 15-Dec-23
- Others
- 01-Nov-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 06-May-25
- 04-Apr-25
- POM
- 05-May-25
- 01-Apr-25
- POM
- 31-Jan-25
- 10-Jan-25
- EGM
- 17-Sept-24
- 14-Aug-24
- AGM
- 06-Jul-24
- 07-Jun-24
- POM
- 13-Jan-24
- 20-Dec-23
- EGM
- 23-Sept-23
- 29-Aug-23
- AGM
- 28-Apr-23
- 31-Mar-23
- EGM
- 29-Sept-22
- 05-Sept-22
- AGM



